09.14.2023 - By Lori La Bey
The HOPE Study – Approaching Dementia Treatment Differently
Lori La Bey talks with Ralph Kern, M.D., who is Chief Medical Officer at Cognito Therapeutics, a company developing a disease-modifying at-home therapy for Alzheimer’s Disease. He has over 17 years of biotech experience including senior medical roles at Genzyme, Novartis, and Biogen.
Learn:
About brain changes
Lifestyle factors and genetics
If early diagnosis helps
At home treatment
Light, sound, sensory stimulation
Biophysical changes
Decreased clinic visits
HOPE Study
Watch the Video Interview Below
https://youtu.be/dRY6PWEvZds
Listen and Subscribe to Alzheimer’s Speaks on Apple Podcast
https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432
Listen and Subscribe to Alzheimer’s Speaks on Spotify
https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3
Contact Cognito Therapeutics Inc.
LinkedIn for Cognito Therapeutics - https://www.linkedin.com/company/cognito-therapeutics-inc./
Twitter for Cognito Therapeutics - @cognitotx
LinkedIn for Ralph Kern - https://www.linkedin.com/in/ralphkernsvpbiotech/
Cognito website - www.cognitotx.com
HOPE study website - www.hopestudyforad.com
Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/
Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011.
Alzheimer's Speaks is part of the Senior Resource Podcast Network Support this Show: https://alzheimersspeaks.com/donate-now/ See omnystudio.com/listener for privacy information.